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Abstract 
Pharmaceutical companies entering emerging countries wiU face intellectual 
property conflicts due to issues relating to thc access to medicines of consumcrs in those 
countnes.“Intellectual property conflict" refers to the conflict of intercst which exists 
between manufacturers， who own intellectual property， and consumers， who do not. 
In reviewing the representative literature， there is a focus on the pricing patterns 
(known as differential pricing) of pharmaceuticals. This is a way of setting different prices for 
the same products in different areas or countries， inparticular setting a low price for low-
income consumers. while at the same time maintaining the pharmaceutical companies' profits 
by granting patents. 
In spite of the growing literature on differential pricing， research in the field of 
corporate behavior reviewed has been relatively lcss dctailed. This paper explores the 
issue from a corporate perspective， by examining four R&D-driven PCs in J apan: Takeda 
Pharmaceutical Company Limited (Takeda)， Daiichi Sankyo Company Limited (Daiichi 
Sankyo)， Eisai Co.， L TD (Eisai) and Astellas Pharma Inc. (Astellas)， mainly through the use 
of quantitative data as a means to determine key financial indicators during the period 20∞-
2013 reviewed 
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1. Introduction 
As pharmaceutical markets in developed countries， induding Japan， America and 
Europe mature， attention has tumed to・pharmergingmarkets'.l Pharmaceutical companies 
(hereafter， PCs) have carried out their business in the markets of developed countries， mainly 
in J apan， America and Europe during the past decades. However， because of the falling 
birthrate and depopulation， and rising medical expenses， the govemments in developed 
countries took action to curb medical expenses. especially through promoting generic drugs. 
In addition， many PCs lost their revenues in developed countries because of the impact 
of top-selling products losing their patent protection. At the same time， the markets in 
emerging countries (巴mergingmarkets) were growing. The emerging market will reach 28 
percent of global spending by 2016， compared with 4.8 percent in 2004， as population and 
economic growth contribute to a dramatically higher use of medicines in these markets. 
Moreover， the CAGR of pharmaceuticals markets during the period 2013-2017 is expected to 
・.
be 14-17 percent in emerging countries， compared to 3-5 percent in developed countries.2 In 
short， this tendency indicates that the contribution of revenues from developed markets is 
much less than from emerging markets， and emerging markets have become more attractive 
to PCs. 
On the other hand， PCs which are entering emerging countries will face serious 
problems， such as intellectual property confiicts due to access to medicines and govemment 
regulation related to出IS.‘Accessto medicines' means the problem of low-income consumers 
who cannot afford the drug prices for their treatment. The main issue surrounding access 
to medicines is high drug prices. However， why is it that the same pricing does not cause 
problems of access to medicines in developed markets? One reason for this may be the 
The phrase ・pharmergingmarket' stands for pharm(即日utical)+(em)erging.That is， emerging markets 
targeted by pharmaceutical compan児s.Generally， the pharmaceutical mark巴tsin emerging countries are seen 
as pharmerging markets， like China， Russia， Brazil and India 
2 Source: IMS Health 
httD:/ /www.imshealth.com/deDlovedfiles/ims/GloballContent/lnsI!lhts/Medicines Outlook Through 2016 
Report.pdf (Accessed on 5 Dec. 2013) 
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fact that medical insurance systems in emerging countries have not been fully developed 
Because of these deficient medical Insurance systems. copayment for consumers in emerging 
countries will be higher than that for consumers in developed countries.、Moreover.some 
consumers in some emerging countries have to pay the ful cost of medicines. In spite of 
rapid economic growth in emerging countries. among the population there remains a large 
proportion of low-income households I (for instance. the proportion of low-income households 
in China accounted for 49.4percent of total population in 2010' ).The amount of copayment 
will become a burden for low-income citizens. thus causing the issue of access to medicines. 
To solve this issue. governments in emerging markets have introduced some 
policies. such as the issuing of compulsory licensing to manufacture products (usually called 
generic products). which are provided at a low price to consumers. Compulsory licensing 
is a form of authorization. whereby governments allow someone else to produce patented 
products or processes without the consent of thc patent owner under the TRIPS (Trade甲
Rc!ated Aspects of Intellectua! Property Rights) Agreement. Compu!sory !icensing will not 
benefit PCs. because they earn less than in the situation before the issuing of compu!sory 
!icensing. Under the scheme of compu!sory licensing. PCs only earn a profit of 0.5% of sales. 
based on the pricing of the gencric products (Tsuruhara. 2007. p.43.)" 
In these circumstances. what path will companies take? It seems that. for PCs 
who want to run their business smoothly in emerging markets. it will depend on whether 
they address the issue of access to medicines vo!untarily. thereby eliminating the potential 
for compu!sory licensing; that is. whether they offer medicines at a low price voluntarily. 
However. as pharmaceutica!s require huge R&D costs. it seems that. by setting low prices. it 
would be difficult to recover costs and repay investors 
How much cost is invested in deve!oping a new type of medicine? It takes an 
enormous amount of time and money to develop one new drug. It takes an average of 10-
15 years to develop a new medicine. from the earliest stages of discovery to the time it is 
γhe average copayment for consumers in developed countries is 7-13 percent. compared with 50・100
percent m emergmg countnes 
I According to White Paper on International Economy and Trade (2010). low-income household refers to 
annual disposal income of les than US $5.000 
Source: Websitc of Ministry of Economy. Trade and Industry. http://www.meti.go.jp/report/ 
tsuhaku2011/2011honbun_p/201 L03-l.pdf(Accessed on December 1ぺ2013)
" ror more examples of compulsory licensing please sec thc Website 01 the ]apanese Patent 0世ice:
httD:! /WWW.iDO.go.iロノshirvou/toushin/chousa/odfltrioschousahoukokuI241.odf 
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available for treating patients. The average cost is estimated to be $800 million to $1 bilion.' 
Even though pharmaceuticaJs require huge R&D costs. PCs have to consider the background 
to people's needs or the introduction of low-priced drugs to solve the issue of access to 
medicines (the relationship between access to medicines and IP will be described later) if 
they want to enter the emerging markets. 
Therefore， this paper considers some schemes that might be able to balance the 
IP confiict due to problems of access to medicines， using a case study from the companies' 
perspective. 'Schemes for balancing IP co凶icts'means considering how PCs could benefit 
under the conditions of low pricing， inorder to solve the problem of access to medicines due 
to IP confiicts. 
The paper is structured as follows: Section 2 provides a definition of“intellectuaJ 
property" (IP)， and describes what IP conflicts are (the relationship between access to 
medicines and IP). Section 3 reviews and analyzes the theoreticaJ literature about IP confiicts. 
Section 4 discusses a methodology to interpret the data available. Section 5 presents some 
empirical findings regarding studies of pharmaceutical manufacturers目 Section6 provides 
some tentative conclusions. 
2. Concepts of intellectual prope吋yand intellectual prope同yconflict 
2.1 The concept of intellectual property 
The World Intellectual Property Organization (WIPO) detines“intellectual property" 
(IP) as creations of the mind， including inventions， literary and artistic works， and symbols， 
names， images， and designs used in commerce. It is a wide ranging definition. In practice， 
the definition of IP may be limited and varies according to different research outcomes and 
viewpoints. For instance， Ghauri. Pervez N.， and Rao， P.M. (2009) refers to IP as technology-
based intangible assets， from the perspective of the IT industry. 
For the purposes of this paper， the term "intellectual property" (IP) refers to a 
valued part of a creation of the mind， which would be able to generate profit for the given 
company. It divides into two types: one is protected by IPRs (intellectual property rights)， 
such as patents， copyright. and so on; the other is not protected by IPR， such as ideas or 
Source: Website of PhRMA 
hto:/ /www.ohrma.orll/sites/default!files/../rd brochure 022307.odt (Accessed on September 19'1'.2013) 
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designs for a new product. In business management. IPs are interpreted as a kind of business 
resource (like a factory)， that is a tool to generate profit. On the other hand， there are some 
IPs which are unable to generate profit for a company， but which require maintenance costs， 
and they are seen as negative assets. Therefore， they cannot be considered as IPs here. 
How does IP generate profit for a company? One sort of IP， which is not protected 
by IPR， like ideas， are sales resources. This could make a difference with other competitors 
and such differences could create opportunities， ifchosen by consumers， which then lead to 
increased sales. Another sort of IP， which is protected by IPR， such as a patent， has exclusive 
rights and wil bar price competition as a resu1t of competition with other rivals: therefore it 
is a tool to secure profit (Doi. 2008: 893). 
2，2 The relationship between Intellectual Property and access to medicines 
The relationship between Intellectual Property and access to medicines， known here 
as the “Intellectual Property confiict・" refers to the confiict of interest which exists between 
manufacturers， who own intellectual property， and consumers， who do not. In this paper， 'the 
interest of manufacturers' refers to sales， profit. or revenue: and ・theinterest of consumers' 
means access to medicine邑fortreatment 
As described above. the issue of intellectual property conflict relates to high 
drug prices. Previous studies， as in Cottingham， ].， and Berger， M. (2011)， claim that high 
drug prices always resulted from patents owned by PCs. On the other hand， because of 
the characteristic of intellectual property that it is intangible and easily imitated， a patent 
system is needed， Generally， PCs apply for a patent to protect the knowledge they generate， 
a process which often gives them a monopolistic control over new drugs for a set period of 
time. Because the technology is easy to imitate， PCs wil lose market share and profit once 
the technology is copied by other competitors (the results are similar to a patent expiring). In 
this way， PCs wil lose opportunities to recover costs. and incentives for future research wil 
diminish. 
To many， itmay seem that the advent of the drug (or patented drug) has simply 
widened the gap between developed and emerging markets. Furthermore. even though 
patents may in theory cnable a firm to charge a high price. this may not be in a firm's self-
interest in markets where the consumers cannot afford to pay (Danzon. P. i¥l.，巴ta1. 2003) 
For this reason. the issue of access to medicines relative to patented intellectual property is 
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called the intellectual property confiict 
3. Literature Review-Differential pricing 
Representative studies focus on ‘differential pricing' (also known as tiered pricing， or 
price discrimination)， which sets different prices for the same products in different areas or 
countries; that is to say that a high price is set in high-income countries， and a low price is 
set in low-income countries (Danzon， P.M， etal.， 2003; Fra叫c，R. し2011)，based on the price 
elasticity of demand 
Danzon， P.M. et al. (2003)， Frank R. L. (2011)， and Mazummdar， M， and Banerjee， D.
S. (2012)， consider that differential pricing is a bilateral way to balance IP confiicts between 
PCs and consumers. This is because differential pricing， especially setting a low price， could 
provide low-income consumers with easy access to medicines. At the same time， PCs could 
benefit more from differential pricing than from uniform pricing (Frank， R.1.， 2011， p.l540) 
by taking advantage of the elasticity of demand. Given the sensitivity of consumers' demand 
for a product to changes in price， generally speaking low-income consumers wil have more 
elastic demand， meaning that if the price decreases， their consumption will increase (the 
market is expanded) (Frank， R. L.， 2011， p.l539). The consequent increase in consumption wil 
lead to increased sales. 
On the other hand， the PCs' problem is their high R&D expenses，叩dthey also have 
to add in production costs (such as materials costs) due to the expanding scale of production 
as consumption rises. Under these conditions of high cost and low prices， how could PCs 
benefit? Regarding this question， Danzon， P. M et a1. (2003) describe the concept of pricing 
standards; that is， a set price under or near the marginal cost. whilst Frank， R. 1. (2011) 
proposes an approach by reducing fixed costs 
Although there is a growing amount of literature on differential pricing， Moon， S.
et al. (2011)叩 dLopert， R.et al. (2002) rejected this idea as it has two shortcomings: a small 
market scale and a requirement for a low-cost production capability. To be effective， pricing 
by elasticity of demand is dependent on a large-scale market. but if the market scale is 
small， an increase in sales cannot be expected. Furthermore， ifPCs do not have a low-cost 
production capability to manage increasing production costs caused by a larger market size， 
differential pricing can only work out in the short term， but it is di血cultto continue with this 
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in the long term. 
4. Methodology 
In spite of the growing amount of literature focusing on differential pricing， a 
theoretical approach which is limited， research in the field of corporate behavior on how 
to balance the IP conflict has been relatively less detailed. This paper explores the issue 
from the perspective of the company by examining four leading PCs in J apan: Takeda 
Pharmaceutical Company Limited (Takeda). Daiichi Sankyo Company Limited (Daiichi 
Sankyo)， Eisai Co.， LTD (Eisai) and Astellas Pharma lnc. (Astellas)， mainly through the use of 
quantitative data as a means of determining key日nancialindicators during the period 2000-
2013 reviewed. Although the four firms are considered to be rather similar with regard to 
their reasons for entering the markets of emerging countries (that is， to recover their lost 
revenues in developed countries)， essentially the way that they have entered these markets 
reveals unique differences when one analyzes certain key elements， such as their strategies 
to enter developing countries. Takeda and Daiichi Sankyo acquired a generic manufacturer， 
Eisai built a factory in the emerging countries， and Astellas introduced regional strategies， 
including a strengthened sales network. The objective of the four firms was similar， that is to 
reduce production costs to supply lower priced drugs， although their practices are different 
As indicated， much reliance is placed on quantitative data and the next section of 
this paper provides a quantitative examination of Takeda， Daiichi Sankyo， Eisai and Astellas 
in terms of their respective corporate investments and financial performance from 2000-2013目
5. Some empirical findings 
The four companies are leading R&D-driven pharmaceutical companies in ]apan. 
although their sales volumes are different. The major markets of the four companies are 
J apanese， European and American. The net sales， net incomes， ROE and share price of each 
company have decreased due to the impact of top-selling products losing patent protection 
in the American market. which is a major market of the four companies (see Table 1). For 
example. the key financial indicators of Takeda， whose patent protection for its top-selling 
product. T AKEPRON. expired in Nov. 2009. have decreased rapidly since March 2011 (the 
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tiscal year of the ]apanese company ends on Mar 31)， as seen in Table 2. This is one of the 
reasons that the four companies entered the emerging countries' market. 
The four companies have been expanding their businesses in emerging countries 
since 2008 by acquiring generic manufacturers， building factories and introducing regional 
strategies in the emerging countries. The resultant tinancial performance of each company is 
児島ctedin Table 2， Table 3， Table 4 and Table 5. 
Takeda has rapidly increased its sales in emerging countries through the acquisition 
of generic manufacturers. Takeda acquired Nycomed International Management GmbH 
(Nycomed) in 2011 and Multilab Industria e Comercio de Produtos Farmaceuticos Ltda 
(Multilab) in 2012， both of which have a strong business base in the emerging countries， 
including market share and a sales network. Sales have increased， however revenues 
have decreased because of increasing operating expenses. particularly increasing sales 
administrative expenses (see Figure 1). Takeda has acquired generic manufacturers， meaning 
that personnel cxpenses have also increased. due to an increase in the number of sta任
Daiichi Sankyo，d who acquired Ranbaxy Laboratories Limited (Ranbaxy)， a generic 
manufacturer. has rapidly increased its sales in emerging countries. Ranbaxy has a large 
market share and a strong sales network in the emerging countries. Actual¥y， sales results in 
the emerging countries were almost achieved by Ranbaxy alone 
The financial results of Daiichi Sankyo are similar to Takeda; that is， despite 
increaSIng己ale己， the revenues have decrea邑eddue 1.0 an increase in operating expenses. 
especial¥y increased administrative expenses. 1n addition， Daiichi Sankyo transferred an 
al¥owance to cover the confiict between Ranbaxy and the US Food and Drug Administration 
(FDA) in 2012， and they achieved agreement in May， 2013. Daiichi Sankyo spent事38.8bil¥ion
to deal with this conflict目 Nevertheless，the conflict arose again when the FDA issued 
an import alert against drugs produced at Ranbaxy's newest facility in Mohali. India， in 
September， 2013. This case affected the tinancial performance of Daiichi Sankyo， and as a 
result their revenues wiU decrease in 20149 
ド DaiichiSankyo was cstablished in 2005 through thc mcrgcr of Sankyo Company. Limited and Daiichi 
Pharmaceutical Company. Limited. Thus. the data of 2以)0-2α)5in Table 3 and Figur巴2ar巴simpleadditions of 
the figures for Daichi and Sankyo 
Daiichi Sankyo has to manufacture products (incllding gcneric versions of a Pfizer Inc. cholesterol 
lowering drug and Eisai Co. Alzheimer's drug) in the U.S. plants as its low-cost Indian plants are banned by 
the FDA. Drug manufacturing costs in India are said to be about half of those in developed countries. thls 
increasing costs wil afect their revenues 
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Eisai built a factory in 1ndia in 2009. Eisai supplies generic drugs and lower priced 
drugs from this plant. and it has also strengthened its sales network. 
Regarding the company's financial performance， as shown in Table 4， sales in 
developed markets started to decrease from 2011. and this was related to the impact of its 
leading products losing their patent protection. At the same time， the sales in emerging 
countries have increased， litle by litle. Consequently， in spite of overall decreasing sales， 
Eisai secured its profit through reduced operating expenses (Figure 3). 
The activities of Astellasll are different from the other three companies. In addition 
to implementing ways to reduce costs， Astellas has executed certain regional strategies， 
including introducing drugs which meet the needs of consumers in emerging countries and 
strengthening their sales network to sel patented drugs. The strategy is vital for Astellas to 
be trusted and chosen by its customers. through enhancing customer satisfaction based on 
strengthening the sales network. Astellas has implemented this method of strengthening its 
sales network. not only in developed markets but also in emerging markets 
Table 5 shows that Astellas is recovering from a fal in sales， which was due to 
the impact of leading products having lost their patent protection in developed markets the 
earliest among the fourωmpanies. The reason for this trend may be due to the efficacy of 
strengthening the sales network. In the case of pharmaceuticals， sales targets arc pharmacies 
and hospitals (doctors). If pharmacies and hospitals make out prescriptions for the PCs' 
products then the PCs' sales and profits will increase even though the products might have 
lost their patent protection. Consequently. Astellas is maintaining its net income as well as 
net sales as it suppresses its trading expenses effectively (as shown in Figure 4). 
The data from the four companies reveals three facts: 
The companies have achieved the objective of supplying low-priced drugs by 
reducing costs in order to secure their profit. especially by reducing sales administrative 
expenses. Is this method of reducing sales administrative expenses enough for improving 
profit? This is not likely. It seems that reducing R&D costs， which account for a large 
proportion of trading expenses. may also be needed. Of course. R&D is seen as the driving 
force that leads to sus 
'" Astellas was formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co。しtd.and 
Fujisawa Pharmaccutical Co. Ltd. Therefore. the data of 2000-2005 in Table 5 and Figurc 4 are simple 
additions of figures for Yamanouchi and Fujisawa 
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core technology and outsourcing other research， more costs can be reduced while 
maintaining sustainability. In fact. Pfizer works in this way to reduce R&D costs. As a result. 
Pfizer has reduced their R&D costs from $9，074 million in 2011 to $7，870 million in 2012.1 
Secondly， Takeda and Daiichi Sankyo lost revenues despite increasing sales. The 
financial results of Takada and Daiichi Sankyo showed that the cost of lower priced drugs is 
not offset by the resultant increase in sales volumes (Grover， A. et al. 2012). This fact argues 
against differential pricing based on price elasticity of demand. The cost of lower pricing 
means the cost of intr吋 ucinglow pricing. In this paper. it refers to the cost of acquiring a 
generic manufacturer. including increasing personnel expenses and paying settlements to the 
FDA. Nevertheless， itis di伍cultto say that Takeda and Daiichi Sankyo failed in the short-
term. as the approach of considering consumer needs (low-priced drugs) wil determine the 
PCs' long-term success. Therefore a long-term perspective is necessary in order to judge the 
activities of the four companies 
Thirdly， the case of Daiichi Sankyo， (the battie between Ranbaxy and the FDA)， 
reveals that working with a cross-division management system is ftawed. The fact is that this 
is not only the case for Daiichi Sankyo， but also for Takeda12 and most ]apanese companies. 
The issue for these companies， which lack some technologies and knowledge after acquiring 
foreign companies. is that they try to keep the introduction of foreign managers with a 
considerable， broad business experience to a minimum， and this has become a vital question. 
Regarding this question， itmight be necessary for ] apanese companies to learn from the 
way that Takeda is reforming its corporate governance system.13 However， as corporate 
governance systems are not within the scope of this paper. and furthermore it is a big issue 
needing more research. 1 would prefer to have another opportunity to discuss it. 
6. Conclusion and further study 
In reviewing representative literature that focuses on the differential pricing of 
1 Pfizer Inc. 2012， Annual report 
1， Mr. Hasegawa. president and CEO of T汰eda，said that 'we failed in the management of foreign subsidiary 
companies (Nycomed and Mutilab) because of the lack of a manager who had broad business experience'， in
an interview with Nihon Keizai Shimbun. on December 1st. 201:3 
J:l Source: Website of Takeda Pharmaceutical Company Limited 
htD:/ /www.takeda.co.iD/news/2013/20131130 607.html (Accessed on D氏 ember1¥2013 ) 
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pharmaceuticals， we have considered the approach of setting low prices for low-income 
consumers whi!e securing the profit of a PC， as a way of balancing the IP conflict due to 
access to medicines. This has received widespread support from industry， society， and 
academics. Nevertheless， the practice of 'differential pricing' as part of corporate behavior 
has been relatively less detai!ed 
This paper has explored the issue from a corporate perspective， by examining four 
R&D-driven PCs in J apan. The paper has examined the activities of four companies based 
on their annual reports， and discusses the results of this case study. The data from the four 
companies reveals that they balance the intellectual property issue by supplying low-priced 
drugs; however， they do not mention the real pricing standards they used. Regarding pricing 
standards， 1 plan to carry out some interviews to analyze this as part of future research. 
The limitation of this research is that the four companies run their businesses in 
di妊erentregions， although in the same segment of emerging countries. 
Table 1: Patent Expiration and Decreasing Sales (in billions of Yen) 
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182 一一一BUSINESSREVIEW -一一
Table 2: Key Financial indicators of Takeda 
(in billions of Yen， for the year ended March 31) 
Items 20∞ 2001 2002 20国 2004 卸価 20個 2007 20伺 20個 201。2011 2012 2013 
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Note: The segment of developed countries includes ]apan， North America， France， 
Italy， England and Ireland. The segment of developing countries includes 
China， Russia/CIS， Brazil， Turkey， Latin America and Indonesia. 
Source: Takeda， 2000-2013， Annual Report. 
Table 3: Key Financial indicators of Daiichi Sankyo 
(in billions of Yen， for the year ended March 31) 
Iterr帽 20田 2001 2002 20田 004 20慣 2.0国 2007 問団 20明 2010 2011 2012 2013 
S.抱.In由四胸囲d
873.6 8454 862 870.9 8981 目92.4 839.9 798 841 2 768 734.4 771.5 
阿閣内B'.
Sa抱sIn err帽retna: 166 16.8 19.7 21 21 23.9 26.2 30.5 40.2 44.2 11 0.9 199.4 204.3 226.3 
markels 
N.t田畑s 890.2 862.2 881.1 891.9 919.1 916 ・925.9 929.5 880.1 842.1 952.1 967.4 938.7 997.8 。開ratlng制問n醐揖 686.5 7106 7495 746.7 770.9 7754 771.2 793.2 723.3 753.2 日56.6 845.3 840.5 897.3 
Tradlng属urDlus 安03.7 1516 133宏 145.2 148.2 141 154.7 1363 156.8 88.9 955 122.1 98.2 100.5 
Net Inoome 66.9 71 70.2 47.4 70.1 85.5 87.7 78.6 97.7 6引 5.5 41.9 70.1 10.4 66.6 
R&日制問n... 98.6 11 0.7 127.7 140.1 145.7 144 158.7 170.7 163.5 184.5 196.8 194.3 185.1 183.0 
Bcoamslmc oen arsnhinag 問pEVgBrn〉 119.49 107.75 135.35 6304.22 5945 99.62 14.75 94.64 
Olv回目nd雷同岡田r
25 60 70 80 60 60 60 60 
Eロmmonsha聞〈咽n)
ROE(S) 7.3 6.3 7.8 620.5 4.9 8.2 1.3 7.9 
Sha聞岡田(yan) 2.685 3.610 2.945 1.648 1.751 1.606 1.508 1.815 
Note: 1) The segment of developed countries includes ]apan， North America and 
Europe. The segment of developing countries includes China， Brazil， Thailand， 
India， Africa and Latin America. 
2) The figures for 2000-2005 are simple additions of the figures for Daiichi 
and Sankyo. 
Source: Daiichi Sankyo， 2006-20013， Annual Report. 
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Table 4: Key Financial indicators of Eisai 
(in billions of Yen， for the year ended March 31) 
「ー
lterT隠 2000 2001 2002 2003 200< 2005 2006 2007 2008 20国 2010 2011 2012 2013 
s.抱5in developed 
299.5 356.9 42'17 457.5 "90.3 521.1 56J.1 650.4 706.5 753.4 771.6 733.6 610.6 530.1 markets 
Sales In emerglng 
3.0 4.s 7.0 9.1 9.9 11.9 
markats 
17.6 23.7 27.8 28.3 31.6 35.3 37.4 43.6 
Net sales 302.5 361.7 431.7 466.6 500.2 533 601.3 674.1 /34.3 781.7 803.2 168.9 646 ~13_7 
0"，，司ting0)(岡田副S 265.4 302.7 359 390.7 417.' 446.2 50~.6 561;.8 716.6 689.9 716日 655.B 552.3 468.4 
T rading surplus 37.1 59 72.7 75.9 83.1 86.8 95.7 105.3 17.7 91.8 86.4 113.1 95.7 105.3 
Net inc日間 11.3 23.3 36.5 41 501 55.5 63.4 70.6 617.0 47.7 40.3 67.4 58.5 48.3 
R&D ex田 nses 46.7 49.6 55 59.7 69 18.3 83.2 108.3 225.4 156.1 179.1 145 125.1 120.04 
Baslc earning四ヨ『
3864 78.68 123.5 141.2 1721 193.4 221.9 247 凸59.8 167.3 141.6 236.5 205.3 169.4 common sha開 (ven)
Dlvlden由田岡田f
21.5 23 29 32 36 56 90 120 130 140 150 150 150 150 CDm間 nsha冊〈咽nl
ROE<sl 35 6.9 10，3 109 12.4 12.6 13 13 品34 10.9 9.6 16.4 143 10.9 
S岡田p!"ice(四 nl 2.705 3.120 3，150 2'日5 2.820 3.540 5，130 5，650 3.400 2.880 3.335 2.984 3，290 4.200 
Note: The segment of developed countries includes ]apan， America and Europe. 
The segment of developing countries includes China， lndia and the Middle-East 
Source: Eisai， 2000-2013， Annual Report. 
Table 5: Key Financial indicators of Astellas 
(in billions of Yen， for the year ended March 31) 
Itoms 2000 2001 2002 2003 2004 2005 2005 2007 2008 2009 2010 2011 2012 2013 
Sales in develo田 d
717.3 7491 8H.9 日779 日969 845.9 marlats 8596 8947 944.6 845.9 8832 902 9337 962.7 
s地al『ehsatis n e me rghng 5.5 63 77 10.7 9.7 16.1 196 >57 278 27.2 30 331 357 429 
Nut sales 722.8 755.4 822.7 。887 906.6 862 879.4 9206 912.6 9657 97-49 9539 9694 1 ()()!).6 
0""目 tingex四聖nses 591.9 62:.1.9 601.6 "120.9 7-48.9 669.8 6白6.3 730.1 696.6 715.3 788.4 H:H n 日37日 851.7 
R&D ex匝 nses 100.4 1066 122.3 1293 1-43.7 127.6 1-47.1 1679 13-4.5 159.1 195.6 2173 169 R 1820 
Tradlng sur凶us 1309 131.5 141.1 1678 157.7 192.2 193 1905 275.9 2504 1864 1192 131 5 153.9 
Net inco何時 80.' 60.8 81.3 88.5 101.5 59.5 103.7 1313 117-'" 171 1223 67.7 ?日 2 目2.9
8asic earning回『
8.B 11.3 161 16 11 7 6.5 7.7 日Cロm"回 nsha開{四n)。ividends田岡同〈田ye『n 
CDm町田nshare(ven) 1 B4 34407 
34989 356.11 261日4 146.49 169.38 180.4 
日OE(，叫 70 BO 110 120 125 125 125 13B 
Sha田岡田(yun) ~-，-~!Q 5，080 3，860 3.020 3.3日5 3.冊。 3.~OO 5，060 
Note: 1) The segment of developed countries includes ]apan. America. Canada. Latin 
America and Europe. The segment of developing countries includes China. 
Thailand. Vietnam and Malaysia 
2) The figures for 2000-2005 are simple additions of the figures for 
Yamanouchi and Fujisawa 
Source: Astellas， 2006-2013， Annual Report. 
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Figure 1 The cost structure of Takeda 
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。%
2蜘 12001120021200312似 1200512揃 12∞712制 1200912010120111201212013 
スOpe凶噌P叫 tma喝in 18.57123.47127.98129.70134.20134.31133.23135.13130.78119.92128.66125泌 117.5617.87
平R初回penseratio 18.37 19.32 19.鈍 111.87111例 112.59113.99114.81120.06129叫 20.22120.35118.68120.82
災 Salead同協同U時制限階何回 122.61123.87125.59127.5212お6.4灯叫7司|ドμ2お5必 i伊2幻7.1412泌6ι.純ω叫|ドμ2泌.6.59124叫お.ιs邸5/2μ3ι却9129.4泊3オi抑34.7
巳Depreciationand amorti凶朗日tio13.6213.49 12.83 12.20125912.7812.371 2.21 12.31 17.681 7.8317.521 5必 pω
.Salesc.田口制。 146.83139.85133.62128.71124.80124.86123.27121.43120.26118.82119.45122.38128.71128.74
Source: Takeda. 2000-2013. Annual Report. 
Figure 2 The cost structure of Daiichi Sankyo 
100% 
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40% 
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20% 
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。%
2鮒 1200112∞21200312捌 1200512蹴 1200712榔 /2制12010120111201212013 
父Operati噌 P悶，fitm時 in 118.57123.47127.98129.70134.20134.31133.231お 13130.78119.叫28“125.86117.5617.87
平R&D割問問e問。 18.3719.3219.98111.8711l.94IU.59113.99114ぉ 120.06129.45120.22120.35118.68120.82
公Saleadministra抑制児問団ω 122.61123.871ぉ59127.52126.471ぉ46127.14126.43126.59124.14123且5123.8912.9約 134.76
.、 Depreci田ionand amortizationratio 13.6213.49 12.8312.201 2.5912.7812.371 2.21 12.3117.6817.8317.5215.6217.80 
.Sa出 costratio 146.83139.85133.62128.71124.80124.86123.27121.43120.26118.82119.45122.38128.71128.74 
Note: The figures for 2000-2005 are simple additions of the figures for Daiichi and 
Sankyo 
Source: Daiichi Sankyo. 2006-2013. Annual Report 
一一 How10 Balance the Inlelectual Property Conflict: a Case Study 0/ Japanese Pharmaceutical ωmp抑 esin Emerging Countries --185 
H Operatir習profitmargin 
t R&D expense ratio 
100% 
90% 
80% 
70% 
60% 
50% 
40% 
30% 
20% 
10% 
。%
Figure 3 The cost structure of Eisai 
~ Sale administ目別四割問問eratio
Depr回副ona nd a mortiz'凶 onratio 14.991 4.15 13.541 3.861 3.701 4.201 4.1613.98 い鎚 16.2816ω 15.661ι441755
.5al"5∞民団tio 130.28127.2312351121.99119.43118.48117.38116.21116.1811951120.01121.82126.76130ヨ5
Source: Eisai. 2000-2013. Annual Report 
公Ope悶討f喝profitmargin 
平R&D制限悶eratio 
Figure.4 The cost structure of Astellas 
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N 5ale抑制strativeexpense ratio 122.61123.87125.59127.52126.47125.将|幻.14126.43126.鈎124.14123.85123.89129伺 134.76
L 阪府民iati加 andam侃 i訓何冊目。13.6213.4912.8312.201 2.5912.7812.3712.2112.311 7.6817.8317.521 5.6217.80 
.Sales c出t日ω146.83139ι5133.62128.71124.8012刈.86123.27121.43120.26118.82119.45122.38128.71128.74
Note: The figures for 2000-2005 are simple additions of the figures for Yamanouchi 
and Fujisawa. 
Source: Astellas. 2006-2013. Annual Report 
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